Skip to main content
    E

    Elicio Therapeutics Inc. (ELTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.48
    -0.02 (-1.33%)

    Market Cap: $42.46M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Elicio Therapeutics Inc. (ELTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Elicio Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$39.57M, operating cash flow was -$36.95M and free cash flow was -$36.97M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$7.98M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $37.71M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$28.31M+883.1%98.5%-138.8%-192.8%
    Dec 2020$2.88M+93.7%58.7%-1919.2%-2781.5%
    Dec 2019$1.49M-63.1%23.6%-2595.2%-2734.2%
    Dec 2018$4.03MN/A90.6%-356.0%-497.0%
    Dec 2013$6.58M-9.8%51.8%-6.0%9.6%
    Dec 2012$7.30MN/A49.7%-5.7%4.2%
    Annual, fiscal years ended Dec 2012 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2013Dec 2012
    Revenue$0$0$0$0$28.31M$2.88M$1.49M$4.03M$6.58M$7.30M
    Cost of revenue$0$0$0$0$433.00K$1.19M$1.14M$380.00K$3.17M$3.67M
    Gross profit$0$0$0$0$27.88M$1.69M$351.00K$3.65M$3.41M$3.62M
    Research and development$24.90M$33.66M$23.85M$18.10M$48.70M$38.98M$29.79M$9.15M$196.01K$0
    Operating income-$37.71M-$44.99M-$35.74M-$23.73M-$39.31M-$55.27M-$38.59M-$14.34M-$397.80K-$419.22K
    Net income-$39.57M-$51.90M-$35.20M-$28.21M-$54.57M-$80.11M-$40.66M-$20.02M$632.24K$307.30K
    EBITDAN/AN/A-$33.94M-$23.62MN/AN/AN/A-$14.34M$62.54K$1.96M
    Fiscal years ended Dec 2012 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$1.17M$0$0$0$0
    Gross profit$0$0$0-$286.00K$0$0$0-$305.00K$0$0$0-$286.00K
    Operating income-$8.45M-$10.43M-$10.60M-$8.84M-$8.04M-$10.09M-$10.74M-$13.48M-$10.34M-$10.92M-$10.24M-$9.39M
    Net income-$7.98M-$8.22M-$11.82M-$7.72M-$10.08M-$10.56M-$11.21M-$14.00M-$18.84M-$7.23M-$11.83M-$8.95M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $9.41M by $9.16M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2013Dec 2012
    Total assets$25.86M$28.18M$27.15M$22.66M$96.51M$47.35M$11.89M$26.63M$11.06M$11.03M
    Current assets$19.31M$20.69M$16.35M$10.72M$91.25M$42.30M$6.11M$25.68M$2.62M$2.06M
    Cash and equivalents$18.56M$17.62M$12.89M$6.16M$88.76M$34.61M$5.57M$25.51M$2.06M$1.40M
    Total liabilities$24.23M$39.49M$15.77M$13.75M$15.01M$137.80M$30.47M$7.72M$6.60M$6.79M
    Short-term debt$0$901.00K$910.00K$692.00K$952.00K$51.43M$6.88MN/A$122.18K$115.58K
    Long-term debt$9.41M$20.03M$0N/AN/A$635.00KN/AN/AN/AN/A
    Shareholder equity$1.64M-$11.31M$11.37M-$102.14M$81.51M-$90.45M-$18.59M$18.91M$2.34M$1.71M
    Fiscal years ended Dec 2012 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$39.60M$31.33M$22.69M$25.86M$28.28M$29.53M$28.14M$28.18M$38.39M$15.75M$24.48M$27.15M
    Total liabilities$20.75M$23.39M$24.13M$24.23M$24.47M$27.69M$19.24M$39.49M$57.37M$17.40M$19.61M$15.77M
    Cash and equivalents$30.90M$23.48M$14.95M$18.56M$20.61M$22.09M$18.35M$17.62M$26.02M$3.42M$11.85M$12.89M
    Shareholder equity$18.85M$7.94M-$1.44M$1.64M$3.82M$1.83M$8.90M-$11.31M-$18.99M-$1.65M$4.87M$11.37M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$36.95M-$37.07M-$32.69M-$22.18M-$52.64M-$22.89M-$24.59M-$8.02M
    Capital expenditures$16.00K$87.00K$66.00K$654.00K$382.00K$41.00K$242.00K$0
    Free cash flow-$36.97M-$37.16M-$32.76M-$22.83M-$53.02M-$22.93M-$24.83M-$8.02M
    Dividends paidN/AN/A$2.36M$0N/AN/AN/AN/A
    Share repurchasesN/AN/A$150.00K$0N/AN/AN/AN/A
    Investing cash flow-$16.00K-$84.00K-$32.00K-$654.00K-$382.00K-$41.00K-$242.00KN/A
    Financing cash flow$36.70M$42.32M$38.61M$21.20M$107.17M$52.41M$4.89M$31.74M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$10.36M-$8.16M-$11.64M-$6.80M-$11.09M-$8.95M-$10.12M-$8.74M-$7.27M-$8.93M-$12.12M-$9.89M
    Capital expendituresN/AN/A$0$16.00K$0$0$0$45.00K$42.00K$42.00K$0$0
    Free cash flowN/AN/A-$11.64M-$6.81M-$11.09M-$8.95M-$10.12M-$8.79M-$7.32M-$8.97M-$12.12M-$9.89M
    Last 12 quarters

    Frequently Asked Questions About ELTX

    What is Elicio Therapeutics' annual revenue?

    Elicio Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Elicio Therapeutics profitable?

    No. Elicio Therapeutics reported net income of -$39.57M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ELTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$36.95M minus capital expenditures of $16.00K produced free cash flow of -$36.97M.

    How much debt does Elicio Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $9.41M, short-term debt of $0 and cash and equivalents of $18.56M.